The evidence base for tirzepatide as monotherapy is robust, with pivotal trials including SURMOUNT-1 demonstrating significant weight reduction in adults with obesity, and SURPASS trials establishing glycemic efficacy in type 2 diabetes
If people turn to supplements marketed with claims of boosting immunity, Austin said, its likely theyre not following the evidence on what would actually protect against Covid-19
has consulted for Kallyope (New York) and the FR/FMG laboratories recieved industrial funding for other projects from MedImmune/AstraZeneca, LGC and Lilly, which has not influenced this study in any way
In a research context comparing tirzepatide to semaglutide on a purely GLP-1-mediated endpoint, that affinity gap matters: at equivalent molar doses, tirzepatide engages GLP-1R less than semaglutide does
Ear infections: These are often bacterial but can be viral